MedPage Today on MSN12d
TYK2 Inhibitor Scores Two Wins Outside Plaque PsoriasisThe TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...
Hosted on MSN1mon
Scientists peel away the mystery of JAK enzymes, which play roles in everything from eczema to ulcerative colitis"Our results indicate that interferon-alpha-1 and interferon-alpha-2 can recruit different JAK members with unexpected promiscuity; however, optimal signaling activity requires JAK1 and TYK2." ...
MedPage Today on MSN9d
Rapid Improvement in Atopic Dermatitis With Dual JAK/TYK2 InhibitorORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in ...
Targeting JAKs and TYK2 In recent years, small-molecule oral treatments targeting Janus kinases (JAKs) and tyrosine kinase 2 (TYK2) have emerged, providing another option to approach a variety of ...
A once-daily TYK2 inhibitor was safe and “highly effective” in adults with moderate to severe plaque psoriasis, according to a presenter. Image: Adobe Stock. The primary endpoint was the ...
The presentations will reveal findings on A-005's potent inhibition of TYK2 signaling in immune and CNS resident cells, which could play a role in treating neuroinflammatory diseases. Jörn Drappa ...
Alumis announced positive Phase 2 OLE results for ESK-001, a TYK2 inhibitor for moderate-to-severe plaque psoriasis, showing sustained clinical improvements. Alumis Inc. has announced positive 52 ...
ICP-488 is an oral, potent and selective TYK2 allosteric inhibitor. By binding to the JH2 domain, ICP-488 blocks the signal transduction of IL-23, IL-12, type 1 IFN and other inflammatory ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback